The United States Patent and Trademark Office (USPTO) has granted patent US12582605B2 to Glatt GmbH for "Extended release formulations of cannabinoids." The patent, filed on July 16, 2019, and granted on March 24, 2026, describes compositions designed for the extended release of cannabinoids such as Δ9-tetrahydrocannabinol and cannabidiol. These compositions include a population of particles, each potentially containing the cannabinoids, drug-releasing agents, surfactants, and a core, which may be a porous bead.

This patent grant represents a new intellectual property asset in the pharmaceutical sector, specifically concerning cannabinoid-based drug delivery. While not a regulatory rule, it signifies innovation and potential future product development in this area. Companies involved in pharmaceutical manufacturing, particularly those working with cannabinoids, should be aware of this granted patent as it may impact their freedom to operate or inform their own research and development strategies. No immediate compliance actions are required for regulated entities, but it highlights a developing area within pharmaceutical R&D.